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ABSTRACT
Aims: This study aims to examine the metabolic
effects of intensification or initiation of insulin
treatment with biphasic insulin 50/50, and determine
the predictors of responders or non-responders to
biphasic insulin 50/50.
Methods: A cohort of 2183 patients ≥18 years with
diabetes, newly treated with biphasic insulin 50/50
between January 2000 and May 2012, were sourced
from UK General Practices via The Health Improvement
Network (THIN) database. Baseline clinical parameters
of 1267 patients with suboptimal glycated hemoglobin
(HbA1c) >7.5% (>58 mmol/mol) who had received
background insulin regimens for at least 6 months
preceding biphasic insulin 50/50 were compared
against 12-month outcome data. Responders were
defined as those with HbA1c <7.5% (58 mmol/mol)
and/or HbA1c reduction of ≥1% (10.9 mmol/mol) at
12 months. Comparative analyses were carried out on
subgroups of 237 patients initiating insulin therapy
with biphasic insulin 50/50, and between users of the
Humalog Mix50 (HM50) versus Insuman Comb 50
(IC50). Associations were examined using t tests and
multivariate logistic regression techniques.
Results: The overall mean HbA1c reduction at
12 months as a result of intensification and initiation with
biphasic insulin 50/50 was 0.5% (5.5 mmol/mol) and
1.6% (17.5 mmol/mol), respectively. Adjusted ORs show
obesity (body mass index >30 kg/m2), treatment duration
for ≥9 months, and baseline HbA1c are independent
determinants of responders. In addition, stratified for
baseline HbA1c levels, HM50 was associated with better
HbA1c outcome compared with IC50.
Conclusions: biphasic insulin 50/50 is effective for
achieving glycemic control in suboptimal HbA1c levels,
especially among obese patients with insulin-treated
diabetes. Stratified for baseline HbA1c, HM50 was
associated with improved HbA1c outcome compared
with IC50.
INTRODUCTION
The introduction of insulin therapy to
achieve adequate glycemic control in patients
with type 2 diabetes mellitus (T2DM) is
inherent to the progressive deterioration of
the pancreatic β-cell function.1 2 There is no
consensus about the most appropriate
insulin regimen to be chosen,3 but National
Institute for Health and Care Excellence
(NICE) guidelines recommend initiating
insulin therapy with human neutral protam-
ine Hagedorn insulin or a long-acting analog
(basal insulin) injected at bedtime or twice
daily according to the patient’s need.4 When
glycemic control is inadequate with basal
insulin, therapy can be intensiﬁed with pran-
dial insulin (which may include a premixed
therapy or basal–bolus regimen). Basal–bolus
insulin has been shown to be useful for con-
trolling preprandial and postprandial blood
glucose levels, as well as for lowering glycated
hemoglobin (HbA1c) levels,5 6 although we
have shown that in routine practice, glycemic
control remains suboptimal in many patients
receiving a basal–bolus insulin regimen.7
In people without diabetes, basal insulin
secretion represents approximately 50% of
KEY MESSAGES
▸ Limited data are available to determine the
appropriate place of use for premixed biphasic
insulin 50/50 (Humalog Mix50 and Insuman
Comb 50) in routine clinical practice, compared
with other lower mix insulin formulations (eg,
mix30 or mix25).
▸ Using real-world clinical data from a UK primary
care cohort, we have shown that biphasic insulin
50/50 is effective for achieving glycemic control
in suboptimal glycated hemoglobin (HbA1c)
levels, especially among obese (body mass
index >30) patients with insulin-treated diabetes.
▸ Humalog Mix50 is more effective than Insuman
Comb 50.
▸ These findings could form a basis for a rando-
mized clinical trial on obese insulin-treated
patients with diabetes.
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the total secretion, with the remaining 50% being meal
related.8 Among patients with T2DM requiring intensive
insulin therapy regimens in the form of multiple daily
injections or insulin pump therapy, both regimens
required 50% basal and 50% rapid-acting insulin follow-
ing dose titration.9 Based on these, a biphasic insulin
50/50 containing 50% each of rapid-acting and basal
insulin (a mid-mix regimen) was developed to provide
the physiological advantages of rapid-acting and long-
acting insulin in the convenience of a premixed formu-
lation.10 Indeed, intensiﬁcation of insulin therapy
(where patients’ blood glucose levels remain suboptimal
after receiving biphasic insulin aspart 30/70, biphasic
human insulin 30/70, or biphasic insulin lispro 25/75)
has been shown to be achieved by switching to premixed
regimens with greater prandial coverage (HM50).11–13
Insuman Comb 50 (IC50)—a combination of 50%
soluble insulin and 50% crystalline protamine insulin––
is also available as a biphasic insulin 50/50 regimen.
There is, however, limited postmarket surveillance and/
or real-world evidence assessing the effectiveness of
switching to HM50 or IC50 regimens in patients with
suboptimal HbA1c levels. This study aims to investigate
the effectiveness of the biphasic insulin 50/50 regimen
(HM50 and IC50) in patients with persistently subopti-
mal HbA1c and examine the clinical and metabolic
parameters that predict glycemic response in people
with T2DM.
METHODS
Study design and data source
We conducted a retrospective cohort analysis of data
from The Health Improvement Network (THIN) data-
base, which contains anonymous patient data from more
than 400 general practices throughout England and
Wales. The database has been validated at the practice
and dataset levels by comparing its demographics, mor-
bidity, mortality, prevalence, and geographical rates with
various national data sources. The database contains
information on all past and current medical diagnoses
(coded using read codes) and prescribed medications
(coded using British National Formulary).
Study population
The study population comprises a cohort of patients
who were identiﬁed to have T2DM, and were registered
to a practice for more than 12 months before the index
date (ie, between January 1, 2000 and the end of the
study— May 16, 2012). The cohort comprised patients
with a suboptimal glucose control (HbA1c) level above
7.5% (58 mmol/mol), who were prescribed other forms
of insulin regimens before the index date and were
≥18 years. Standardized computerized routines to
include programing language and use of algorithms were
used to obtain the relevant data using Read codes.
Information was extracted on patients diagnosed with
diabetes and previous insulin prescriptions for at least
6 months preceding conversion to biphasic insulin 50/50
regimen. Six months duration was used because THIN
data suggests 95% of repeat prescriptions for insulin have
a periodicity of less than 6 months.
Exposure and outcomes
Exposure was deﬁned as two or more prescriptions of
HM50 or IC50, with a follow-up period of 12 months
from the index date. Alternatively, the 90th day record-
ing of HbA1c levels was used, or the date of switching
to, or adding another glucose-lowering drug. The
primary outcome was a change in HbA1c levels after
exposure. Responders are deﬁned as patients whose
12-month HbA1c fell below 7.5% (58 mmol/mol) or
who experienced HbA1c reduction of more than 1%
(10.9 mmol/mol) at 12 months when compared with
baseline. The secondary outcome was a measure of the
association between changes in HbA1c level and abso-
lute change in weight at 12 months after the index
date.
Covariates
Covariates were selected a priori on the basis of clinical sig-
niﬁcance. These are baseline demographic and clinical
parameters, referred to as ‘predictors’ of interest. They
include age, gender, social deprivation (measured using
Townsends index scores),14 body weight, body mass index
(BMI), baseline HbA1c, total cholesterol levels, low-density
lipoprotein, high-density lipoprotein (HDL), triglycerides,
systolic and diastolic blood pressures, smoking status,
lipid-lowering therapies, antihypertensive drugs, aspirin,
oral antidiabetic drugs (OADs), drugs, duration of dia-
betes drug treatment, and comorbidity. In addition, the
background insulin treatments the patients received prior
to index date, for example, basal, bolus, or premixed regi-
mens, were included as determinants of interest.
Statistical analysis
Baseline characteristics that might distinguish between
responders and non-responders to HM50/IC50 therapy
were analyzed using the χ2 and t tests. Multiple logistic
regressions were carried out to identify covariates that
predict a response (HbA1c change) within 12 months.
ORs for predictors and confounding variables were cal-
culated and expressed as point estimates with a 95% CI,
at the conventional statistical signiﬁcance level of 0.05.
Missing data were accounted for with multiple imputa-
tions using chained equations.15
Subgroup and secondary analyses
Correlation and linear regression analyses were per-
formed to assess the relationship between changes in
HbA1c and weight at 12 months. Analysis was carried
out on a subgroup of patients who were not prescribed
any insulin prior to study entry (initiation group).
Subgroup analysis for efﬁcacy in end point changes in
HbA1c from baseline was performed between HM50
and IC50 treatment groups. Baseline HbA1c was
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categorized into three strata: <8% (<64 mmol/mol), 8 to
<9% (64–75 mmol/mol), and ≥9% (≥75 mmol/mol).
Sensitivity analysis
Sensitivity analysis was carried out to compare results of
multiply imputed data with complete data, and to assess the
reliability of the outcomes and the impact of missing data.
All analyses were conducted using Stata Software, V.13.16
Bias
Our analysis employed the ‘new user’ design to minim-
ize biases associated with prevalent use of insulin.17
Prior exposure to basal, bolus, and other premixed
insulin regimens could also be a factor on the causal
pathway for response, thereby introducing confounding
by indication.18 These potential biases were minimized
by conducting analysis within a cohort of new users
who did not receive prescriptions for biphasic insulin
50/50 in the 12 months prior to study entry. The
cohort was restricted to patients with at least two repeat
prescriptions of biphasic insulin 50/50 for an estimated
12-month follow-up to reduce the risk of bias intro-
duced by the different durations of treatments.17 We
also restricted the cohort to individuals whose treat-
ment with insulin for at least 6 months preceding con-
version had failed.
RESULTS
General patient characteristics
Of the 2183 users of biphasic insulin 50/50, 1267
patients fulﬁlled the criteria for cohort entry as outlined
in ﬁgure 1 and 237 people formed the subgroup of
patients who had not received insulin prior to the index
date. The cohort had a mean age of 61 years and 54%
were men. In total, 684 (54%) of the cohort were pre-
scribed HM50.
Response to intensification therapy
Our analysis focused on HbA1c response to intensiﬁca-
tion with biphasic insulin 50/50. In total, 457 (36%) of
patients responded to intensiﬁcation therapy, based on
criteria for responders described previously. Responders
were not signiﬁcantly different with age, sex, weight,
social deprivation strata, smoking status, or previously
prescibed medications. In addition, responders were
unrelated to the majority of comorbid conditions and
clinical parameters. Baseline mean HbA1c was signiﬁ-
cantly higher among responders compared with non-
responders (10.2% (88 mmol/mol) vs 9.3% (78 mmol/
mol), p<0.001), and responders had a slightly lower
HDL at baseline (1.3 vs 1.4 mmol/L, p=0.03; table 1).
Overall, intensiﬁcation with biphasic insulin 50/50
resulted in a 0.5% (5.5 mmol/mol) reduction in HbA1c,
0.9 kg increase in weight, and 0.3 kg/m2 increase in
BMI at 12 months. Responders had a signiﬁcantly
Figure 1 Study selection flow
diagram. HbA1c, glycated
hemoglobin; T2DM, type 2
diabetes mellitus.
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Table 1 Baseline characteristics of Humalog Mix50 users
Characteristics
Total
(n=1267)
Responders
(n=457)
Non-responders
(n=810)
OR (95% CI)
(unadjusted) p Value
Exposure/predictors
Age (years) 61 (15) 62 (14) 61 (15) 1.01 (1.00 to 1.01) 0.1
Sex
Male 682 (54) 251 (37) 431 (63) 1
Female 585 (46) 206 (35) 379 (65) 0.93 (0.74 to 1.17) 0.9
Townsend deprivation
I—least deprived 226 (18) 84 (37) 142 (63) 1
II 269 (21) 94 (35) 175 (65) 0.91 (0.63 to 1.31) 0.6
III 284 (22) 103 (36) 181 (64) 0.96 (0.67 to 1.38) 0.8
IV 274 (22) 94 (34) 180 (66) 0.88 (0.61 to 1.27) 0.5
V—most deprived 214 (17) 82 (38) 132 (62) 1.05 (0.71 to 1.54) 0.8
BMI (kg/m2) 30.4 (6.8) 31 (6.9) 30 (6.7) 1.02 (1.00 to 1.04) 0.01
BMI categories (kg/m2)
Normal 259 (20) 79 (31) 180 (70) 1
Overweight 406 (32) 140 (34) 266 (66) 1.20 (0.86 to 1.68) 0.3
Obese 602 (48) 238 (40) 364 (40) 1.49 (1.09 to 2.03) 0.01
Weight (kg) 85.8 (2.) 87 (20) 85 (20) 1.00 (1.00 to 1.01) 0.1
Baseline HbA1c (%) 9.6 (1.5) 10.2 (1.7) 9.3 (1.3) 1.54 (1.41 to 1.68) <0.001
BP (mm Hg)
Systolic BP 139 (19) 139 (19) 139 (19) 1.00 (1.00 to 1.01) 0.6
Diastolic BP 76 (11) 76 (11) 76 (11) 1.00 (1.00 to 1.01) 0.6
Total cholesterol (mmol/L) 4.7 (1.3) 4.7 (1.3) 4.7 (1.2) 1.01 (0.92 to 1.10) 0.9
HDL (mmol/L) 1.3 (0.6) 1.3 (0.6) 1.4 (0.5) 0.78 (0.63 to 0.98) 0.03
LDL (mmol/L) 2.6 (1.1) 2.6 (1.1) 2.6 (1.1) 1.02 (0.92 to 1.14) 0.7
Triglyceride (mmol/L) 2.4 (6.6) 2.7 (4.9) 2.2 (7.3) 1.01 (0.99 to 1.03) 0.2
Smoking status
Never smoked 577 (46) 204 (35) 373 (65) 1
Current smoker 226 (18) 76 (34) 150 (66) 0.93 (0.67 to 1.28) 0.6
Ex-smoker 464 (37) 177 (38) 287 (62) 1.13 (0.87 to 1.45) 0.9
Use of medications
Antihypertensive 1076 (85) 381 (35) 695 (65) 1.83 (0.61 to 1.13) 0.2
Lipid-lowering therapy 911 (72) 341 (37) 570 (63) 1.24 (0.96 to 1.60) 0.1
Aspirin 693 (55) 255 (37) 438 (63) 1.07 (0.85 to 1.35) 0.5
Oral antidiabetic
Gliptin 44 (3) 16 (36) 28 (63) 1.01 (0.54 to 1.89) 0.9
GLP1 61 (5) 25 (41) 36 (59) 1.24 (0.73 to 2.10) 0.4
Metformin 1115 (88) 400 (36) 715 (64) 0.93 (0.66 to 1.32) 0.7
Sulfonylurea 465 (37) 177 (38) 288 (62) 1.15 (0.90 to 1.45) 0.3
Thiazolidinedione 133 (11) 49 (37) 84 (63) 1.04 (0.72 to 1.51) 0.8
Other 95 (8) 35 (37) 60 (63) 1.03 (0.67 to 1.60) 0.9
Previous insulin therapy
Premixed regimen 925 (73) 325 (35) 600 (65) 1
Basal insulin 253 (20) 95 (38) 158 (62) 1.11 (0.83 to 1.48) 0.5
Bolus 89 (7) 37 (42) 52 (58) 1.31 (0.84 to 2.05) 0.2
Comorbid conditions
CHD 636 (50) 237 (37) 399 (63) 1.11 (0.88 to 1.40) 0.4
PAD 313 (25) 120 (38) 193 (62) 1.14 (0.87 to 1.48) 0.3
Cerebrovascular 252 (20) 87 (35) 165 (65) 0.92 (0.69 to 1.28) 0.6
Heart failure 228 (18) 96 (42) 132 (58) 1.37 (1.02 to 1.83) 0.04
Hypoglycemia 549 (43) 193 (35) 356 (65) 0.93 (0.74 to 1.18) 0.6
Number of Mix50 Rx
2–5 406 (32) 131 (32) 275 (68) 1
6–8 315 (25) 95 (30) 220 (70) 0.91 (0.66 to 1.25) 0.5
9–12 284 (22) 104 (37) 180 (63) 1.21 (0.88 to 1.67) 0.2
≥13 262 (21) 127 (48) 135 (52) 1.97 (1.43 to 2.72) <0.001
Continued
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higher mean (SD) weight increase (1.6 (7.1) vs 0.5 (4.9)
kg, p<0.001) and signiﬁcant mean HbA1c reduction of
1.9% (20.8 mmol/mol) vs 0.3% (3.3 mmol/mol)
increase seen in non-responders (p<0.001).
Main results
After adjusting for the effects of confounders, the inde-
pendent predictors of response to intensiﬁcation with
biphasic insulin 50/50 were obesity (BMI >30 kg/m2; OR,
1.50 (95% CI 1.08 to 2.09), ≥9 months of intensiﬁcation
therapy (OR, 1.98 (95% CI 1.23 to 3.20)), and baseline
HbA1c (OR, 1.55 (95% CI 1.42 to 1.69); table 2).
Comparison between HM50 vs IC50
We compared the metabolic effects of HM50 vs IC50
according to baseline strata for HbA1c values. Overall,
HM50 was associated with a better HbA1c response com-
pared with IC50 (mean reduction in HbA1c of 0.6% vs
0.4% (6.6 vs 4.4 mmol/mol), p<0.001; table 3). The dif-
ference in mean change of HbA1c was approximately
0.5% (95% CI 0.02% to 0.94%) or 5.5 mmol/mol (95%
CI 0.2 to 10.3) lower with HM50 treatment group
compared with IC50 in the baseline HbA1c category
below 8% (<64 mmol/mol). The IC50 group had a
0.06% (95% CI −0.22% to 0.34%) or 0.7 mmol/mol
(95% CI 2.4 to 3.7) lower reduction in HbA1c compared
with HM50 at baseline HbA1c category of 8% to <9%
(64 to <75 mmol/mol). The greatest treatment beneﬁt
was observed in patients within the baseline HbA1c cat-
egory of 9% and above (≥75 mmol/mol), where HM50
was associated with a non-signiﬁcant lower mean differ-
ence (−0.2% (95% CI −0.03% to 0.39%) or
−2.2 mmol/mol (95% CI −0.3 to 4.3)) when compared
with the IC50 treatment group. Mean weight increase at
12 months was not signiﬁcantly different between HM50
and IC50 users (table 3).
Other analyses
Tests for interactions between sex, social deprivation,
and responders were not signiﬁcant at the 5% level, indi-
cating no evidence of effect modiﬁcation across these
groups. A scatter plot of individual patient data shows a
signiﬁcantly negative but weak association between
change in HbA1c and change in weight at 12 months
Table 1 Continued
Characteristics
Total
(n=1267)
Responders
(n=457)
Non-responders
(n=810)
OR (95% CI)
(unadjusted) p Value
Duration of therapy (months)
0–3 111 (9) 27 (24) 84 (76) 1
3–6 106 (8) 33 (31) 73 (69) 1.41 (0.77 to 2.56) 0.3
6–9 133 (11) 48 (36) 58 (64) 1.76 (100 to 3.07) 0.05
9–12 917 (72) 349 (38) 568 (62) 1.91 (1.21 to 3.01) 0.005
BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; GLP1, glucagon-like peptide-1 agonis;
HbA1c; glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PAD, peripheral artery disease.
Table 2 Results of multiple logistic regression analyses
Predictors of response OR (95% CI) (unadjusted) p Value OR (95% CI) (adjusted) LRT p Value
Baseline HbA1c (%) 1.53 (1.40 to 1.67) <0.001 1.55 (1.42 to 1.69) <0.001
BMI categories (kg/m2)
Normal 1 1
Overweight 1.35 (0.94 to 1.94) 0.1 1.40 (0.98 to 2.00) 0.06
Obese 1.35 (0.95 to 1.91) 0.09 1.50 (1.08 to 2.09) 0.02
HDL (mmol/L) 0.91 (0.70 to 1.12) 0.3 – –
Comorbid conditions
Heart failure 1.20 (0.88 to 1.64) 0.2 – –
Number of Mix50 Rx
2–5 1 – –
6–8 0.72 (0.50 to 1.04) 0.08
9–12 0.94 (0.64 to 1.37) 0.7
≥13 1.27 (0.85 to 1.91) 0.2
Duration of therapy (months)
0–3 1 1
3–6 1.64 (0.88 to 3.04) 0.1 1.51 (0.80 to 2.82) 0.2
6–9 1.90 (1.05 to 3.44) 0.04 1.70 (0.94 to 3.07) 0.08
9–12 1.95 (1.15 to 3.31) 0.01 1.98 (1.23 to 3.20) 0.005
BMI, body mass index; HDL, high-density lipoprotein; HbA1c; glycated hemoglobin; LRT, likelihood ratio test.
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(Pearson’s correlation coefﬁcient, r=−0.13; p<0.001;
ﬁgure 2). Change in weight accounts for approximately
1.7% of the total variation in HbA1c change, and for
every unit increase in weight, HbA1c increased by an
estimated 0.04% (0.4 mmol/mol). The subgroup of 237
patients who initiatied insulin therapy with biphasic
insulin 50/50 were examined, and 149 (59%) patients
responded to treatment. The mean (SD) reduction in
HbA1c in the subgroup was 1.6 (2.1) % or 17.5 (23.0)
mmol/mol.
DISCUSSION
Overall, this study showed a signiﬁcant 0.5% (5.5 mmol/
mol) reduction in HbA1c at 12 months after patients
with suboptimal HbA1c from background insulin were
converted to biphasic insulin 50/50. Multiple regression
analysis showed that the presence of obesity and baseline
HbA1c were independent predictors of responders to
biphasic insulin 50/50 therapy. Results showed that
responders to biphasic insulin 50/50 in the main study
cohort were more likely to experience weight gain and
reduction in cholesterol levels, compared with non-
responders. HM50 appears to be superior to IC50 in gly-
cemic outcomes, when stratiﬁed for baseline HbA1c.
Although mean HbA1c improved following conversion
to biphasic insulin 50/50, only 36% of patients
responded to the intensiﬁcation based on our strict def-
inition of responders. This relatively low percentage of
responders to biphasic insulin 50/50 may reﬂect the dif-
ﬁculties in lowering HbA1c in a challenging cohort of
patients with insulin-treated diabetes. This was similar to
our previous study of responders to any insulin therapy
among patients with newly diagnosed diabetes, where
47% of patients responded to any insulin therapy.19
The link between intensiﬁcation of insulin treatment
and weight gain is well recognized.6 20 We7 and others21 22
have previously shown that low BMI is a signiﬁcant pre-
dictor of response to insulin therapy. A study by Nichols
et al on insulin-treated patients with T2DM, for example,
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Figure 2 Relationship between change in glycated
hemoglobin (HbA1c) and change in weight at 12 months.
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showed that lower BMI, younger age, and female gender
were predictors of good glycemic response to insulin.
Furthermore, we have previously shown a threshold BMI
of 34.7 kg/m2, above which patients appeared to have a
reduced response to insulin therapy.7 Thus, the manage-
ment of obese insulin-treated diabetes presents a signiﬁ-
cant therapeutic challenge as clinicians strive to achieve
optimal glycemic targets. To this end, a novel and import-
ant ﬁnding from this study was the observation of
improved HbA1c response to biphasic insulin 50/50,
among obese (BMI >30 kg/m2) compared with non-obese
patients with insulin-treated diabetes. The reason for this
is unclear, as our data cannot be analyzed for the total
amount or frequency of insulin being used per day. We
would speculate, however, that the intensiﬁcation of
insulin therapy by conversion to biphasic insulin 50/50
regimen (from a basal–bolus insulin or a low-mix biphasic
insulin regimen) is often associated with a reduction in
the total amount of insulin used per day (unpublished pre-
liminary observation from our ongoing UK multicentre
audit of HM50 use in clinical practice), which would facili-
tate weight loss, improved compliance, and would confer
glycemic beneﬁts. This is highly relevant given the high
prevalence of obesity among insulin-treated patients with
diabetes. The mean weight gain of 1.6 kg at 1 year
induced by conversion to biphasic insulin 50/50 was com-
parable, if not slightly less than the weight gain of 2.2 kg
with any insulin regimen, observed in our previous study.7
Moreover, in the previous study,7 we observed a mean BMI
increase of 1.13 kg/m2 with any premixed insulin com-
pared with a BMI gain of 0.3 kg/m2 with biphasic insulin
50/50 in the present study. This favorable effect of
biphasic insulin 50/50 on weight observed in this study is
supported by a previous ﬁnding from another study. Kazda
et al23 found that, among patients who started insulin
therapy with either HM50 or Humalog, BMI gain was sig-
niﬁcantly less in the former (0.6±1.1 vs 0.9±1.5, p<0.005),
despite patients taking a higher daily dose of insulin in the
HM50 group (0.59±0.3 U/kg vs 0.50±0.23 U/kg, p<0.005).
In addition, previous studies have shown beneﬁts of HM50
compared with human insulin 70/3013 or Humalog 75/
2523 in reducing postprandial glucose excursion.10 These
beneﬁts were augmented when HM50 was given thrice
daily compared with 70/30 twice daily,11 or 70/30 thrice
daily,24 but equivalent when compared with a basal–bolus
insulin regimen.25 Our data however did not include eth-
nicity and hence our ﬁndings cannot be generalized to all
ethnic groups. Socioeconomic factors did not affect
glucose control.
In the sensitivity analysis of missing data, the associ-
ation between response and baseline predictors gave
similar results for the complete and incomplete cases,
which indicates that missing data were unlikely to bias
the outcome of the study. Nonetheless, our analyses
were subject to some limitations inherent to observa-
tional studies. Potential residual confounders such as
compliance, diabetes duration, indications for insulin
therapy, and differences in insulin regimens or titration
protocols used across different areas in the UK were not
accounted for. We attempted to minimize compliance
bias by restricting the analysis to those who received
more than 6 months of biphasic insulin 50/50 prescrip-
tion from the index date. Also, we did not fully account
for the role of comorbid illnesses, but previous data
suggest that this factor did not affect glycemic control.25
Despite these limitations, our study highlights the effect-
iveness of biphasic insulin 50/50 in real-world practice.
We have shown how simple clinical and demographic
parameters that are available to clinicians and research-
ers may inﬂuence biphasic insulin 50/50 treatment
among patients with suboptimal glucose control.
In summary, the results of this study support the use of
biphasic insulin 50/50 as a therapeutic option, especially
among obese patients with insulin-treated diabetes whose
glucose control remains suboptimal. Improvements in
HbA1c were associated with weight gain and reduction in
cholesterol levels. Our ﬁndings also showed that when
stratiﬁed for baseline HbA1c, HM50 was associated with
greater HbA1c reduction compared with IC50. A robust
randomized controlled trial is required to fully investigate
the effectiveness of biphasic insulin 50/50 among
patients with obesity and diabetes who are unresponsive
to other insulin treatment.
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